The following are exempts of the above reports:

--  XRAY seems to be weathering the downturn well.

--  PAETEC is well positioned with management debt, financial strength
    and...

--  In August, Antigenics raised $20 million through two separate private
    placements of common stock and...

--  Cubist's strong top and bottom line results have been achieved in an
    environment that has been tough for many branded pharmaceuticals.

--  Alkermes performed reasonable in this economic downturn. Its financial
    and operating results remain strong and...

--  During the third quarter BIIB drove a clear acceleration of TYSABRI
    patient growth that puts the drug on a blockbuster run-rate.

You can now access these full research reports along with many others by signing up for free at Analyst Choice or www.analystchoice.com.

About Analyst Choice:

Analyst Choice has combined some of the best financial and technical minds worldwide to bring you an array of free quality equity research and reporting. While the world economy undergoes enormous pressure and unprecedented actions are been taken to avoid the worst and boost the shrinking global economic growth, our analysts brings you a bird's eye view of how the big players in the different key sectors and industries of the NASDAQ and NYSE, are coping. Sign up now by visiting the following link. http://www.analystchoice.com/

AnalystChoice.com is an independent financial research portal and as such has not received any compensation by any of the above mentioned companies.

SOURCE: Analyst Choice

The study will assess the safety and efficacy of multiple doses of ALKS 33 in patients with alcohol dependence and is designed to further define the clinical profile of ALKS 33.

"The advancement of ALKS 33 in the clinic is an important step as we continue to build our proprietary pipeline, which is based on drugs that we believe have a high likelihood of clinical and commercial success," said Elliot Ehrich, M.D., Chief Medical Officer at Alkermes. "We expect to use the results from this phase 2 study to shape our plans for phase 3 clinical development."

The phase 2 study is designed to assess the safety and efficacy of ALKS 33 in patients with alcohol dependence. In this multi-center, double-blind, placebo-controlled study, up to 440 patients will be randomized to receive daily oral administrations of one of three doses of ALKS 33 or placebo for a total of 12 weeks of treatment. The phase 2 study has an adaptive study design which enables an interim analysis after 40 percent of the patients are enrolled and on medication for eight weeks of treatment. The efficacy of ALKS 33 will be evaluated based on the percentage of patients who are abstinent from heavy drinking during the eight-week evaluation phase. Heavy drinking is defined as five or more drinks per day for men and four or more drinks per day for women. The pharmacokinetics and safety of ALKS 33 will also be evaluated.

About ALKS 33

ALKS 33 is an oral opioid modulator that builds on Alkermes' unique understanding of biological pathways and opioid pharmacology as well as the company's clinical and commercial knowledge in the field of addiction. In October 2009, Alkermes presented topline data from two phase 1 clinical trials of ALKS 33. Data from the studies showed that ALKS 33 was generally well tolerated and demonstrated rapid oral absorption, high plasma concentrations and duration of action that supports once daily dosing. ALKS 33 was also shown to successfully block the effects of an opioid agonist for more than 24 hours following a single administration.

About Opioid Modulators

Opioid modulators can act as agonists, antagonists or partial agonists at opioid receptors throughout the body. Emerging biological research and new medicinal chemistry insights now allow for the development of novel opioid modulators with the potential to show enhanced activity at opioid receptor sites and could ultimately lead to improved therapeutic options.

Alkermes, Inc. is a fully integrated biotechnology company committed to developing medicines to improve patients' lives.

((Comments on this story may be sent to health@closeupmedia.com))

The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p less than 0.0002). Based on the positive results of this phase 3 study, Alkermes plans to file a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA) in the first half of calendar 2010. XR-NTX, marketed by Alkermes as Vivitrol, is an opioid antagonist administered once-monthly by intramuscular injection and is approved in the U.S. for the treatment of alcohol dependence. If approved by the FDA for the treatment of opioid dependence, XR-NTX has the potential to be the first and only non-narcotic, non-addictive drug agent available in a once-monthly formulation.

In addition to meeting the primary efficacy endpoint, the six-month phase 3 study met all secondary efficacy endpoints. Data from the intent-to-treat (ITT) analysis show that the median patient taking XR-NTX had 90 percent opioid-free urine screens during the evaluation phase of the study and patients treated with XR-NTX demonstrated a significant reduction in opioid craving compared to placebo as measured by a visual analog scale. XR-NTX was generally well tolerated in the study and no patients on XR-NTX discontinued the study due to adverse events. The most common adverse events experienced by patients receiving XR-NTX during the study were nasopharyngitis and insomnia.

"These robust data show that XR-NTX helped opioid dependent patients become drug-free with just one injection each month," said Dr. Herbert Kleber, Professor of Psychiatry, Director, Division on Substance Abuse, Columbia University. "XR-NTX is a unique formulation that offers patients and physicians a once-monthly, non-addictive medication to help fight this challenging disease."

"Medical treatment for opioid dependence is an established and growing pharmaceutical market, yet there are limitations with currently available therapies," said Richard Pops, Chief Executive Officer of Alkermes. "We look forward to expanding our label beyond alcohol dependence to make XR-NTX available as the first and only non-narcotic, non-addictive, once-monthly treatment option for the millions of patients struggling with opioid dependence."

Alkermes will complete the full analysis of the phase 3 trial data and plans to submit the data for publication in a peer-reviewed journal.

Phase 3 Study Design

The phase 3 randomized, multi-center study was designed to assess the efficacy and safety of XR-NTX compared to placebo treatment in opioid dependent subjects who have been recently detoxified and abstinent from opioids for a minimum of seven days prior to treatment initiation. Two hundred and fifty subjects were randomized to receive once-monthly injections of either XR-NTX 380 mg or placebo in combination with counseling for six months. The primary efficacy endpoint was the response profile based on the rate of urine drug screens that were free of opioids during the last 20 weeks of the 24-week double-blind treatment period, as measured by the cumulative distribution of clean urine screens. The secondary efficacy endpoints in the phase 3 study were the study retention rate, craving scores, self-reported opioid use and the incidence of physiologic opioid dependence. All participants who completed the randomized portion of the study are eligible to continue in an open-label extension phase and receive XR-NTX once-monthly in combination with counseling for an additional thirteen months.

About Opioid Dependence

In addition to the use of heroin, an illegal opioid drug, opioid abuse and addiction includes the non-medical use of FDA-approved opioid analgesics, including prescription pain relievers, and represents a growing public health problem in the U.S. According to the 2008 U.S. National Survey on Drug Use and Health, an estimated two million people aged 12 or older were dependent on or abused pain relievers or heroin.1 The overall cost of prescription opioid abuse in the U.S. has been estimated at $9.6 billion, including health care, criminal justice, and workplace costs.2

Vivitrol is a once-monthly, extended-release injectable medication for the treatment of alcohol dependence and was approved by the FDA in April 2006. The proprietary Medisorb drug delivery technology in Vivitrol enables the medication to be gradually released into the body at a controlled rate over a one-month time period.

Alkermes, Inc. is a fully integrated biotechnology company committed to developing medicines to improve patients' lives.

Vivitrol Full Prescribing Information:

www.vivitrol.com or call 1-800-Vivitrol (1-800-848-4876)

((Comments on this story may be sent to health@closeupmedia.com))

To sign up for our free Profiles & Alerts :: visit http://www.StockMarketingInc.com

email us!! info@StockMarketingInc.com or call 1-866-583-8960

------------------------------------------------------------------------------------------------------------------------------------------------------------

(OTCBB: MTCH - Matech Corp.)

LATEST NEWS!!

MATECH Performs EFS Testing on Bridges for Federal Highway Administration

LOS ANGELES, CA, Nov 16, 2009 -- MATECH Corp. (OTCBB: MTCH) (www.matechcorp.com) is pleased to announce that it will perform services on bridges for the Federal Highway Administration (FHWA) during the remainder of 2009 and 2010. MATECH will utilize its leading technology, the Electrochemical Fatigue Sensor (EFS) System, in these inspections as part of the FHWA's federally mandated Steel Bridge Testing Program (SBTP) Phase II. MATECH's EFS System is the only nondestructive method able to detect growing cracks in bridges as small as 0.01 inches.

A major agency of the U.S. Department of Transportation, the FHWA is responsible for ensuring that America's roads and highways continue to be the safest and most technologically advanced. The FHWA provides financial and technical support to them for constructing, improving, and preserving America's highway system. The agency is provided an annual budget of more than $30 billion.

This effort, set to commence the coming weeks, will involve a week's worth of fieldwork, as well as subsequent analysis and reporting. Results will provide the bridge owner with invaluable information about the growth activity of the cracks in the bridge structural steel members, as well as the efficacy of repairs already completed on the structures.

MATECH has a proven track record of saving bridge owners money through improving bridge management and public safety with its cutting edge technology, the EFS System. Through eliminating subjectivity of inspections for cracking in bridge members (the FHWA has stated that 90% of these cracks are missed with visual inspection), MATECH is helping to eliminate wasted funds by prioritizing repairs and verifying their effectiveness immediately.

"We are very pleased to be continuing this effort with the FHWA," said Robert M. Bernstein, CEO of MATECH. "Results of this Steel Bridge Testing Program will be invaluable to the industry. We anticipate that the results of the program will represent yet another example of the effectiveness and inherent value of our EFS technology." About MATECH MATECH Corp, founded in 1983, is an engineering, research and development company based in Los Angeles, CA. The Company specializes in technologies to measure microscopic fractures in metal structures. MATECH is now marketing its patented Electrochemical Fatigue Sensor (EFS) and other advanced crack-detection technologies to bridge asset managers, railroad companies, and governmental agencies across the United States and internationally. To learn more, please visit: www.matechcorp.com.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: ALKS - Alkermes, Inc.)

LATEST NEWS!!

Alkermes Announces Positive Results from Phase 3 Clinical Study of Naltrexone for Extended-Release Injectable Suspension for the Treatment of Opioid Dependence

-- Once-Monthly, Non-Addictive Treatment Significantly Reduced Opioid Use in Multicenter, Six-Month Study --

CAMBRIDGE, Mass., Nov 16, 2009 -- Company to File for FDA Approval in the First Half of Calendar 2010 -- Alkermes, Inc. (NASDAQ: ALKS) today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002). Based on the positive results of this phase 3 study, Alkermes plans to file a supplemental New Drug Application (sNDA) with the U.S. Food and Drug Administration (FDA) in the first half of calendar 2010. XR-NTX, marketed by Alkermes as VIVITROL(R), is an opioid antagonist administered once-monthly by intramuscular injection and is approved in the U.S. for the treatment of alcohol dependence. If approved by the FDA for the treatment of opioid dependence, XR-NTX has the potential to be the first and only non-narcotic, non-addictive drug agent available in a once-monthly formulation.

In addition to meeting the primary efficacy endpoint, the six-month phase 3 study met all secondary efficacy endpoints. Data from the intent-to-treat (ITT) analysis show that the median patient taking XR-NTX had 90% opioid-free urine screens during the evaluation phase of the study and patients treated with XR-NTX demonstrated a significant reduction in opioid craving compared to placebo as measured by a visual analog scale. XR-NTX was generally well tolerated in the study and no patients on XR-NTX discontinued the study due to adverse events. The most common adverse events experienced by patients receiving XR-NTX during the study were nasopharyngitis and insomnia.

"These robust data show that XR-NTX helped opioid dependent patients become drug-free with just one injection each month," stated Dr. Herbert Kleber, Professor of Psychiatry, Director, Division on Substance Abuse, Columbia University. "XR-NTX is a unique formulation that offers patients and physicians a once-monthly, non-addictive medication to help fight this challenging disease." "Medical treatment for opioid dependence is an established and growing pharmaceutical market, yet there are limitations with currently available therapies," stated Richard Pops, Chief Executive Officer of Alkermes. "We look forward to expanding our label beyond alcohol dependence to make XR-NTX available as the first and only non-narcotic, non-addictive, once-monthly treatment option for the millions of patients struggling with opioid dependence." Alkermes will complete the full analysis of the phase 3 trial data and plans to submit the data for publication in a peer-reviewed journal.

Phase 3 Study Design The phase 3 randomized, multi-center study was designed to assess the efficacy and safety of XR-NTX compared to placebo treatment in opioid dependent subjects who have been recently detoxified and abstinent from opioids for a minimum of seven days prior to treatment initiation. Two hundred and fifty subjects were randomized to receive once-monthly injections of either XR-NTX 380 mg or placebo in combination with counseling for six months. The primary efficacy endpoint was the response profile based on the rate of urine drug screens that were free of opioids during the last 20 weeks of the 24-week double-blind treatment period, as measured by the cumulative distribution of clean urine screens. The secondary efficacy endpoints in the phase 3 study were the study retention rate, craving scores, self-reported opioid use and the incidence of physiologic opioid dependence. All participants who completed the randomized portion of the study are eligible to continue in an open-label extension phase and receive XR-NTX once-monthly in combination with counseling for an additional thirteen months.

About Opioid Dependence In addition to the use of heroin, an illegal opioid drug, opioid abuse and addiction includes the non-medical use of FDA-approved opioid analgesics, including prescription pain relievers, and represents a growing public health problem in the U.S. According to the 2008 U.S. National Survey on Drug Use and Health, an estimated two million people aged 12 or older were dependent on or abused pain relievers or heroin.(1) The overall cost of prescription opioid abuse in the U.S. has been estimated at $9.6 billion, including health care, criminal justice, and workplace costs.(2) About VIVITROL VIVITROL is the first and only once-monthly, extended-release injectable medication for the treatment of alcohol dependence and was approved by the FDA in April 2006. The proprietary Medisorb(R) drug delivery technology in VIVITROL enables the medication to be gradually released into the body at a controlled rate over a one-month time period. For a copy of the VIVITROL full prescribing information, including boxed warning, please visit www.vivitrol.com or call 1-800-VIVITROL (1-800-848-4876).

VIVITROL Important Safety Information in Alcohol Dependence VIVITROL is contraindicated in patients receiving opioid analgesics or with current physiologic opioid dependence, patients in acute opiate withdrawal, any individual who has failed the naloxone challenge test or has a positive urine screen for opioids, or in patients who have previously exhibited hypersensitivity to naltrexone PLG, carboxymethylcellulose or any other components of the diluent.

VIVITROL patients must be opioid free for a minimum of 7-10 days before treatment. Attempts to overcome opioid blockade due to VIVITROL may result in a fatal overdose. In prior opioid users, use of opioids after discontinuing VIVITROL may result in a fatal overdose because patients may be more sensitive to lower doses of opioids. Patients requiring reversal of the VIVITROL blockade for pain management should be monitored by appropriately trained personnel in a setting equipped for cardiopulmonary resuscitation.

Naltrexone has the capacity to cause hepatocellular injury when given in excessive doses.

Naltrexone is contraindicated in acute hepatitis or liver failure, and its use in patients with active liver disease must be carefully considered in light of its hepatotoxic effects.

The margin of separation between the apparently safe dose of naltrexone and the dose causing hepatic injury appears to be only five-fold or less. VIVITROL does not appear to be a hepatotoxin at the recommended doses.

Patients should be warned of the risk of hepatic injury and advised to seek medical attention if they experience symptoms of acute hepatitis. Use of VIVITROL should be discontinued in the event of symptoms and/or signs of acute hepatitis.

VIVITROL is administered as a gluteal intramuscular injection. Inadvertent subcutaneous injection of VIVITROL may increase the likelihood of severe injection site reactions. VIVITROL must be injected using the customized needle provided in the carton. Because needle length may not be adequate due to body habitus, each patient should be assessed prior to each injection to assure that needle length is adequate for intramuscular administration. VIVITROL injection site reactions may be followed by pain, tenderness, induration, swelling, erythema, bruising or pruritus; however, in some cases injection site reactions may be very severe. Injection site reactions not improving may require prompt medical attention, including in some cases surgical intervention.

Consider the diagnosis of eosinophilic pneumonia if patients develop progressive dyspnea and hypoxemia. In an emergency situation in patients receiving VIVITROL, suggestions for pain management include regional analgesia or use of non-opioid analgesics. Alcohol dependent patients, including those taking VIVITROL, should be monitored for the development of depression or suicidal thoughts. Caution is recommended in administering VIVITROL to patients with moderate to severe renal impairment.

The most common adverse events associated with VIVITROL in clinical trials were nausea, vomiting, headache, dizziness, asthenic conditions and injection site reactions.

About Alkermes Alkermes, Inc. is a fully integrated biotechnology company committed to developing innovative medicines to improve patients' lives. Alkermes developed, manufactures and commercializes VIVITROL(R) for alcohol dependence and manufactures RISPERDAL(R) CONSTA(R) for schizophrenia and bipolar I disorder. Alkermes' robust pipeline includes extended-release injectable, pulmonary and oral products for the treatment of prevalent, chronic diseases, such as central nervous system disorders, addiction and diabetes. Headquartered in Cambridge, Massachusetts, Alkermes has research facilities in Massachusetts and a commercial manufacturing facility in Ohio.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: ALTR - Altera Corp.)

LATEST NEWS!!

Altera Delivers Industry's First Serial RapidIO 2.1 IP Solution

SAN JOSE, Calif., Nov 16, 2009 -- Altera Corporation (NASDAQ:ALTR) today announced the immediate availability of the industry's first intellectual property (IP) core supporting the RapidIO(R) 2.1 specification. Altera's Serial RapidIO IP core supports up to four lanes at 5.0 GBaud per lane, addressing the increased bandwidth and reliability needs of the wireless and military markets. The IP core is optimized for Stratix(R) IV FPGAs with embedded transceivers and is supported within Quartus(R) II software v9.1.

The RapidIO 2.1 specification enables increased performance up to 20 GBaud in applications ranging from next-generation wireless basestations, high-performance military systems and DSP farms. Support for the RapidIO 2.1 specification builds upon Altera's complete Serial RapidIO solution, which includes an end-point IP core that is backward compatible to the RapidIO 1.3 specification, reference designs, application notes, testbenches, and interoperability reports with leading digital signal processor and switch vendors. The Serial RapidIO IP core has been qualified against the RapidIO Trade Association's bus functional model and is supported within Altera's 40-nm Stratix IV GX and Stratix IV GT FPGAs and HardCopy(R) IV GX ASICs.

"Serial RapidIO is a popular interface for many of our wireless and military customers who put the utmost importance on system bandwidth and reliability," said Luanne Schirrmeister, senior director of component product marketing at Altera. "Combining the industry's first Serial RapidIO IP core supporting the 2.1 specification with Altera's industry-leading FPGA and transceiver technology solidly positions us to address our customer's most important system requirements, including performance, reliability and scalability." Pricing and Availability The Serial RapidIO IP solution is part of Altera's MegaCore(R) IP library and is available now for evaluation upon download and installation of Quartus II software v9.1. To download the combined Quartus II software and MegaCore IP library, visit: www.altera.com/support/software/download/sof-download_center.html. Licensing and pricing information for the Serial RapidIO IP core is available by contacting your local Altera sales representative. Additional information on Altera's Serial RapidIO solutions can be found at www.altera.com/products/ip/iup/rapidio/m-alt-riophy.html.

About Altera Altera(R) programmable solutions enable system and semiconductor companies to rapidly and cost-effectively innovate, differentiate and win in their markets. Find out more about Altera's FPGA, CPLD and ASIC devices at www.altera.com. Follow Altera via Facebook, RSS and Twitter.

Altera, the Altera logo, and all other words that are identified as trademarks are, unless noted otherwise, Registered, U.S. Patent and Trademark Office, and the trademarks of Altera Corporation in the U.S. and other countries. RapidIO is a trademark of RapidIO Trade Association. All other product or service names are the property of their respective holders.

SOURCE: Altera Corporation

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: AMZN - Amazon.com, Inc.)

LATEST NEWS!!

Amazon Launches Frustration-Free Packaging Certification Program

Customers will benefit from even more hassle-free packaging options available with the introduction of the new certification initiative

SEATTLE, Nov 16, 2009 --Amazon Frustration-Free Packaging program extended to France, Germany, Japan and the United Kingdom --Amazon adds top brands, including Garmin, Logitech, RadioFlyer and Seventh Generation to the Frustration-Free Packaging program Amazon.com, Inc. (NASDAQ:AMZN) today announced the launch of the Frustration-Free Packaging certification program (www.amazon.com/ffp-certification). The new initiative is designed to increase the number of Frustration-Free packaged items available to customers by making it easier for manufacturers to participate in Amazon's Frustration-Free Packaging program.

"Wrap rage is real," said Dr. Nadia Shouraboura, vice president of Global Fulfillment for Amazon. "We launched packaging feedback and we were surprised by the customer participation and response world-wide. Our customers told us they want packaging that is easier to open, and is free of wire ties and impenetrable plastic clamshells. We are launching the certification program to share customer feedback with manufacturers and provide an easy way for manufacturers to modify their packaging to make it Frustration-Free. We want to give customers the best possible experience from the time the order is placed, to when they remove the items from the packaging." The certification initiative provides manufacturers a simple, efficient process for getting packaging analyzed and modified to make it more customer-friendly. Manufacturers interested in getting their packaging Certified Frustration-Free can now submit packaging, at no charge from Amazon, to Amazon's Packaging certification lab, where a team of packaging engineers will analyze the current packaging and either certify it or recommend modifications. Once Amazon certifies that the packaging meets Amazon's Certified Frustration-Free Packaging guidelines (www.amazon.com/ffp-certification), manufacturers can then use the "Certified Frustration-Free" logo on their packaging, alerting customers to expect an easy-to-open, hassle-free experience.

In addition to announcing the Frustration-Free Packaging certification program in the United States, Amazon recently announced it has launched the Amazon Frustration-Free Packaging program in Germany, France, Japan and the United Kingdom.

Amazon initially launched the Frustration-Free Packaging program in the United States in November 2008 with 19 products. The company now has hundreds of products from 30 manufacturers worldwide participating in the program and has just added major brands Garmin, Logitech, RadioFlyer and Seventh Generation.

"Garmin's new Frustration-Free Packaging replaces the previous PVC plastic packaging with easy-to-open, easy-to-recycle corrugated material -- smaller, lighter and made with more than 80 percent recycled material. Our new design reduces packaging volume by approximately 30 percent, so units ship in smaller cartons and ship directly to the customer," said Dr. Min Kao, chairman and CEO of Garmin Ltd. "All of this adds up to packaging that's friendlier for Garmin, Amazon, our customers and the environment." Customers can find the growing selection of Amazon Frustration-Free products at www.amazon.com/frustration-free, where they can also give feedback and rate both Amazon and manufacturers' packaging.

About Amazon.com Amazon.com, Inc. (NASDAQ:AMZN), a Fortune 500 company based in Seattle, opened on the World Wide Web in July 1995 and today offers Earth's Biggest Selection. Amazon.com, Inc. seeks to be Earth's most customer-centric company, where customers can find and discover anything they might want to buy online, and endeavors to offer its customers the lowest possible prices. Amazon.com and other sellers offer millions of unique new, refurbished and used items in categories such as Books; Movies, Music & Games; Digital Downloads; Electronics & Computers; Home & Garden; Toys, Kids & Baby; Grocery; Apparel; Shoes & Jewelry; Health & Beauty; Sports & Outdoors; and Tools, Auto & Industrial.

Amazon Web Services provides Amazon's developer customers with access to in-the-cloud infrastructure services based on Amazon's own back-end technology platform, which developers can use to enable virtually any type of business. Examples of the services offered by Amazon Web Services are Amazon Elastic Compute Cloud (Amazon EC2), Amazon Simple Storage Service (Amazon S3), Amazon SimpleDB, Amazon Simple Queue Service (Amazon SQS), Amazon Flexible Payments Service (Amazon FPS), Amazon Mechanical Turk and Amazon CloudFront.

Amazon and its affiliates operate websites, including www.amazon.com, www.amazon.co.uk, www.amazon.de, www.amazon.co.jp, www.amazon.fr, www.amazon.ca, and www.amazon.cn.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: ANSS - ANSYS, Inc.)

LATEST NEWS!!

ANSYS Named to Software Top 100

Engineering Simulation Software Developer Makes List of World's Largest Software Companies

SOUTHPOINTE, Pa., Nov 16, 2009 -- ANSYS, Inc. (NASDAQ: ANSS), a global innovator of simulation software and technologies designed to optimize product development processes, today announced that it has been named to the Software Top 100(TM), the leading and independent online overview of the world's largest software companies. For the 2009 list, ANSYS placed at 75.

To compile the annual Software Top 100 ranking, software companies are ranked according to their revenues coming from "prepackaged" software sales. Revenues from subscription and support activities (also called "maintenance" contracts) are included; revenues from service activities such as consultancy, training, custom software development and system integration are excluded.

The list is used primarily by the software industry for market and competitive analysis. "ANSYS first appeared in the Software Top 100 in 2007, at position 92," said Balder Verberne, Software Top 100 editor. "The company is consistently growing faster than other large software companies; it climbed to position 79 in 2008 and position 75 in the current ranking." For the current year, revenue growth at ANSYS was 25 percent, while the growth of all companies that made the list was "18 percent on average in defiance of the economic crisis," the editor added.

"It is certainly an honor to be named among the world's largest software companies," said Jim Cashman, president and CEO of ANSYS, Inc. "Even in the face of a global recession and prolonged sales cycles, ANSYS has continued its steady performance. By turning the challenges of the last year into opportunities, ANSYS has maintained its decade-long focus on long-term performance." About Software Top 100 The Software Top 100, first published online in 2003, is the leading and independent overview of the world's largest software companies, ranked by annual software revenues. The list is compiled by the Netherlands-based Top 100 Research Foundation, a not-for-profit foundation solely dedicated to researching and publishing information about the software industry. Over 70,000 websites and online magazines from all over the world link to www.softwaretop100.org as a reference for objective software industry information.

About ANSYS, Inc. ANSYS, Inc., founded in 1970, develops and globally markets engineering simulation software and technologies widely used by engineers and designers across a broad spectrum of industries. The Company focuses on the development of open and flexible solutions that enable users to analyze designs directly on the desktop, providing a common platform for fast, efficient and cost-conscious product development, from design concept to final-stage testing and validation. The Company and its global network of channel partners provide sales, support and training for customers. Headquartered in Canonsburg, Pennsylvania, U.S.A., with more than 60 strategic sales locations throughout the world, ANSYS, Inc. and its subsidiaries employ over 1,600 people and distribute ANSYS products through a network of channel partners in over 40 countries. Visit www.ansys.com for more information.

ANSYS, ANSYS Workbench, Ansoft, AUTODYN, CFX, FLUENT, and any and all ANSYS, Inc. brand, product, service and feature names, logos and slogans are registered trademarks or trademarks of ANSYS, Inc. or its subsidiaries in the United States or other countries. All other brand, product, service and feature names or trademarks are the property of their respective owners.

------------------------------------------------------------------------------------------------------------------------------------------------------------

(NASDAQ: APOL - Apollo Group, Inc.)

LATEST NEWS!!

Apollo Group, Inc.'s University of Phoenix is Recertified by U.S. Department of Education to Participate in Title IV Programs

University's Program Participation Agreement is Non-provisional and Issued for Three-Year Period

PHOENIX, Nov 16, 2009 -- Apollo Group, Inc. (NASDAQ: APOL) ("Apollo Group," "Apollo" or the "Company") today announced that it has been informed by the U.S. Department of Education that its University of Phoenix subsidiary has been recertified for continued participation in student financial aid programs under Title IV of the Higher Education Act. The University's new Program Participation Agreement is not provisional and expires December 31, 2012.

"We take our fiduciary duty of handling Title IV funds extremely seriously and apply the highest standards of care and diligence in administering and accounting for these funds," said Apollo Group President and Chief Operating Officer Joseph D'Amico. "We are pleased with University of Phoenix's recertification and look forward to continuing to participate in Title IV programs, which are largely responsible for enabling our students to pursue higher education and advance their careers and their lives." University of Phoenix's prior certification for participation in Title IV programs expired in June 2007, at which time the University continued to participate in the programs on a month-to-month basis as approved by the Department of Education pending its recertification.

About Apollo Group, Inc.

Apollo Group, Inc. is one of the world's largest private education providers and has been in the education business for more than 35 years. The Company offers innovative and distinctive educational programs and services both online and on-campus at the high school, undergraduate, graduate and doctoral levels through its subsidiaries: University of Phoenix, Institute for Professional Development, College for Financial Planning, Western International University, Meritus University, Insight Schools and Apollo Global. The Company's programs and services are provided in 40 states and the District of Columbia; Puerto Rico; Canada; Latin America; and Europe, as well as online throughout the world (data as of August 31, 2009).

For more information about Apollo Group, Inc. and its subsidiaries, call (800) 990-APOL or visit the Company's website at www.apollogrp.edu.

------------------------------------------------------------------------------------------------------------------------------------------------------------

About StockMarketingInc.com

StockMarketingInc.com is a website that profiles stocks of interest. We are not licensed brokers or financial consultants. The information here is believed to be reliable, but not guaranteed to be accurate by StockMarketingInc.com. Please be advised that the information contained may or may not be complete and is solely for informational purposes only. This is not to be construed as an offer to sell, hold or the solicitation of an offer to buy. Investors are encouraged to seek opinions by their registered brokers or financial advisors after extensive due diligence is performed.

CONTACT: StockMarketingInc.com e-mail: info@StockMarketingInc.com Tel: +1 866 583 8960

((M2 Communications disclaims all liability for information provided within M2 PressWIRE. Data supplied by named party/parties. Further information on M2 PressWIRE can be obtained at http://www.presswire.net on the world wide web. Inquiries to info@m2.com.